Hims & Hers Executives Capitalize on Surge as Insider Sales Reflect Strong Market Confidence.

### Insider Activity at Hims & Hers Health: A Robust Sale Pattern

In recent insider trading activities, executives at Hims & Hers Health Inc. (HIMS) have demonstrated a consistent trend toward selling shares, showcasing a high level of confidence in capitalizing on the current market valuation of their holdings. During the last month up to June 3, 2025, a notable amount of shares have been transacted, primarily through sales.

Leading these activities, Chief Financial Officer Oluyemi Okupe executed significant transactions involving both the conversion of derivative securities and subsequent sales. On May 28, Okupe converted 6,437 shares and then sold 11,581 shares at an impressive price of $52.98 per share, accumulating $613,537. Similarly, Officer Soleil Boughton sold 3,233 shares at $55.87 per share on May 27, summing to $180,628.

Notably, Andrew Dudum, CEO of the company, completed an influential transaction on May 16 by selling 175,661 shares at a price range between $57.84 to $59.27 per share, reaching a total of $10,251,388. This sale followed a conversion of 125,335 derivative shares at a notably lower conversion price of $2.43 per share.

Analyzing the pattern over the past few months, there's a growing tendency among top executives at HIMS to realize gains from the company's rising share prices. The past several months showcased a robust increase in the share price, peaking at $60.22 per share on transactions dated May 15. This represents a substantial appreciation compared to earlier this year, when shares were trading between $20.05 to $35.00 as recorded over various transactions in March and April.

Despite the pronounced sales, the overall ownership by major institutional investors remains stable, highlighting confidence in the company's long-term potential. Blackrock Inc., Vanguard Group Inc, and Goldman Sachs Group Inc. continue to be the top institutional holders, collectively maintaining a substantial portion of the shares. As of the latest filings in March 2025, these institutions have slightly adjusted their holdings, with Goldman Sachs notably increasing its share, reflecting a strategic confidence investment in Hims & Hers Health.

Conclusively, despite insider sales signaling a potential peak in current share valuations, the strategic involvement of key institutional stakeholders underlines optimism about the company’s sustained growth trajectory. Investors and market watchers should closely monitor any shifts in insider selling patterns as potential indicators for market sentiment shifts at Hims & Hers Health Inc.